The paradox of response and survival in cancer therapeutics

Research output: Contribution to journalArticle

Abstract

Although most patients with cancer respond to therapy, few are cured. Moreover, objective clinical responses to treatment often do not even translate into substantial improvements in overall survival. For example, patients with indolent lymphoma who achieved a complete remission with conventional-dose therapies in the prerituximab era did not experience a survival advantage over similar patients treated with a "watch and wait" approach. Several studies have also shown that neither the magnitude nor the kinetics of clinical response has an impact on survival in multiple myeloma. Recent data suggesting many malignancies arise from a rare population of cells that exclusively maintains the ability to self-renew and sustains the tumor (ie, "cancer stem cells") may help explain this paradox that response and survival are not always linked. Therapies that successfully eliminate the differentiated cancer cells characterizing the tumor may be ineffective against rare, biologically distinct cancer stem cells. New methods for assessing treatment efficacy must also be developed, as traditional response criteria measure tumor bulk and may not reflect changes in rare cancer stem cell populations. In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches.

Original languageEnglish (US)
Pages (from-to)431-434
Number of pages4
JournalBlood
Volume107
Issue number2
DOIs
StatePublished - Jan 15 2006

Fingerprint

Stem cells
Neoplastic Stem Cells
Tumors
Survival
Neoplasms
Cells
Therapeutics
Hematologic Neoplasms
Multiple Myeloma
Population
Kinetics
Lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

The paradox of response and survival in cancer therapeutics. / Huff, Carol Ann; Matsui, William; Smith, B Douglas; Jones, Richard J.

In: Blood, Vol. 107, No. 2, 15.01.2006, p. 431-434.

Research output: Contribution to journalArticle

@article{f207a0f062a542c8840a223faf018033,
title = "The paradox of response and survival in cancer therapeutics",
abstract = "Although most patients with cancer respond to therapy, few are cured. Moreover, objective clinical responses to treatment often do not even translate into substantial improvements in overall survival. For example, patients with indolent lymphoma who achieved a complete remission with conventional-dose therapies in the prerituximab era did not experience a survival advantage over similar patients treated with a {"}watch and wait{"} approach. Several studies have also shown that neither the magnitude nor the kinetics of clinical response has an impact on survival in multiple myeloma. Recent data suggesting many malignancies arise from a rare population of cells that exclusively maintains the ability to self-renew and sustains the tumor (ie, {"}cancer stem cells{"}) may help explain this paradox that response and survival are not always linked. Therapies that successfully eliminate the differentiated cancer cells characterizing the tumor may be ineffective against rare, biologically distinct cancer stem cells. New methods for assessing treatment efficacy must also be developed, as traditional response criteria measure tumor bulk and may not reflect changes in rare cancer stem cell populations. In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches.",
author = "Huff, {Carol Ann} and William Matsui and Smith, {B Douglas} and Jones, {Richard J}",
year = "2006",
month = "1",
day = "15",
doi = "10.1182/blood-2005-06-2517",
language = "English (US)",
volume = "107",
pages = "431--434",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - The paradox of response and survival in cancer therapeutics

AU - Huff, Carol Ann

AU - Matsui, William

AU - Smith, B Douglas

AU - Jones, Richard J

PY - 2006/1/15

Y1 - 2006/1/15

N2 - Although most patients with cancer respond to therapy, few are cured. Moreover, objective clinical responses to treatment often do not even translate into substantial improvements in overall survival. For example, patients with indolent lymphoma who achieved a complete remission with conventional-dose therapies in the prerituximab era did not experience a survival advantage over similar patients treated with a "watch and wait" approach. Several studies have also shown that neither the magnitude nor the kinetics of clinical response has an impact on survival in multiple myeloma. Recent data suggesting many malignancies arise from a rare population of cells that exclusively maintains the ability to self-renew and sustains the tumor (ie, "cancer stem cells") may help explain this paradox that response and survival are not always linked. Therapies that successfully eliminate the differentiated cancer cells characterizing the tumor may be ineffective against rare, biologically distinct cancer stem cells. New methods for assessing treatment efficacy must also be developed, as traditional response criteria measure tumor bulk and may not reflect changes in rare cancer stem cell populations. In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches.

AB - Although most patients with cancer respond to therapy, few are cured. Moreover, objective clinical responses to treatment often do not even translate into substantial improvements in overall survival. For example, patients with indolent lymphoma who achieved a complete remission with conventional-dose therapies in the prerituximab era did not experience a survival advantage over similar patients treated with a "watch and wait" approach. Several studies have also shown that neither the magnitude nor the kinetics of clinical response has an impact on survival in multiple myeloma. Recent data suggesting many malignancies arise from a rare population of cells that exclusively maintains the ability to self-renew and sustains the tumor (ie, "cancer stem cells") may help explain this paradox that response and survival are not always linked. Therapies that successfully eliminate the differentiated cancer cells characterizing the tumor may be ineffective against rare, biologically distinct cancer stem cells. New methods for assessing treatment efficacy must also be developed, as traditional response criteria measure tumor bulk and may not reflect changes in rare cancer stem cell populations. In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=30444446406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444446406&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-06-2517

DO - 10.1182/blood-2005-06-2517

M3 - Article

VL - 107

SP - 431

EP - 434

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -